Allergan (AGN) and Editas Tie Up to Treat Eye Diseases – Nasdaq
MedCity News |
Allergan (AGN) and Editas Tie Up to Treat Eye Diseases
Nasdaq The agreement includes early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. CRISPR (Clustered Regularly Interspaced Short … Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing … Editas, Allergan Ink $90M CRISPR-Based Eye Drug Deal Allergan and Editas announce $90M CRISPR deal |
